The estimated Net Worth of Joseph C. Iii Cook is at least $57.4 Million dollars as of 18 March 2021. Mr. Cook owns over 12,229 units of Castle Biosciences stock worth over $3,860,349 and over the last 5 years he sold CSTL stock worth over $53,227,575. In addition, he makes $286,714 as Independent Director at Castle Biosciences.
Joseph has made over 29 trades of the Castle Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 12,229 units of CSTL stock worth $195,664 on 18 March 2021.
The largest trade he's ever made was buying 334,745 units of Castle Biosciences stock on 29 July 2019 worth over $5,355,920. On average, Joseph trades about 47,232 units every 20 days since 2019. As of 18 March 2021 he still owns at least 124,407 units of Castle Biosciences stock.
You can see the complete history of Mr. Cook stock trades at the bottom of the page.
Joseph C. Cook III, Jr. serves as Independent Director of the Company. Since February 2003, Mr. Cook has served as a Managing Director at Mountain Group Partners, an investment firm with investments in the life sciences, agtech and technology sectors. From January 2001 until February 2003, Mr. Cook served as a Director, Private Placements in the Investment Banking Group of Robert W. Baird & Co. Incorporated. Mr. Cook also previously served as a Vice President in the Investment Banking Group at J.C. Bradford & Co. Mr. Cook serves on the board of directors of MiNDERA Corp., a non-invasive transcriptome testing company, and Cerebrotech Medical Systems, Inc., a machine learning cerebral diagnostic company. Mr. Cook holds a B.A. degree in Economics from Davidson College.
As the Independent Director of Castle Biosciences, the total compensation of Joseph Cook at Castle Biosciences is $286,714. There are 8 executives at Castle Biosciences getting paid more, with Derek Maetzold having the highest compensation of $4,132,350.
Joseph Cook is 49, he's been the Independent Director of Castle Biosciences since 2018. There are 12 older and no younger executives at Castle Biosciences. The oldest executive at Castle Biosciences, Inc. is David Kabakoff, 72, who is the Independent Director.
Joseph's mailing address filed with the SEC is C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD, TX, 77546.
Over the last 5 years, insiders at Castle Biosciences have traded over $378,509,770 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold, and Joseph C. Iii Cook. On average, Castle Biosciences executives and independent directors trade stock every 6 days with the average trade being worth of $632,640. The most recent stock trade was executed by Derek J Maetzold on 9 September 2024, trading 2,586 units of CSTL stock currently worth $76,184.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences executives and other stock owners filed with the SEC include: